ECM
KYTX icon

ExodusPoint Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

ExodusPoint Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Sell
11,476
-37,535
-77% -$333K ﹤0.01% 1463
2026
Q1 		$423K Buy
+49,011
New +$408K ﹤0.01% 1232
2024
Q4 		– Sell
-41,984
Closed -$205K – 2150
2024
Q3 		$205K Buy
+41,984
New +$324K ﹤0.01% 1452

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

ExodusPoint Capital Management's KYTX Position: Q2 2026 in Review

ExodusPoint Capital Management reduced its Kyverna Therapeutics (KYTX) stake by 77% in Q2 2026, selling an estimated $333K and leaving 11,476 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #1463.

ExodusPoint Capital Management first reported a position in KYTX in Q3 2024 and has held it in 3 quarters since. The position peaked at $423K in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • ExodusPoint Capital Management held 11,476 shares of Kyverna Therapeutics worth $102K as of Q2 2026.
  • ExodusPoint Capital Management sold 37,535 Kyverna Therapeutics shares in Q2 2026, an estimated $333K.
  • Kyverna Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q2 2026, its #1463 holding.
  • ExodusPoint Capital Management first reported a position in Kyverna Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • ExodusPoint Capital Management's Kyverna Therapeutics position peaked at $423K in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.